What is the projected market valuation of the Neuroprotective Agent Market by 2035?

The Neuroprotective Agent Market is projected to reach a valuation of 16.41 USD Billion by 2035. Read More

What was the market valuation of the Neuroprotective Agent Market in 2024?

In 2024, the Neuroprotective Agent Market was valued at 8.123 USD Billion. Read More

What is the expected CAGR for the Neuroprotective Agent Market during the forecast period 2025 - 2035?

The expected CAGR for the Neuroprotective Agent Market during the forecast period 2025 - 2035 is 6.6%. Read More

Which therapeutic area is expected to dominate the Neuroprotective Agent Market?

Alzheimer's Disease is expected to dominate the Neuroprotective Agent Market, with a projected valuation increase from 2.5 USD Billion to 5.2 USD Billion. Read More

What are the key mechanisms of action in the Neuroprotective Agent Market?

The key mechanisms of action include Antioxidants, Anti-inflammatory agents, Neurotransmitter Modulators, and Calcium Channel Blockers, with respective valuations indicating growth. Read More

Which companies are considered key players in the Neuroprotective Agent Market?

Key players in the Neuroprotective Agent Market include Bristol Myers Squibb, Eli Lilly and Company, Pfizer Inc., and Novartis AG. Read More

What is the projected growth for the Injectable route of administration in the Neuroprotective Agent Market?

The Injectable route of administration is projected to grow from 2.5 USD Billion to 5.0 USD Billion by 2035. Read More

How does the Home Care segment perform in the Neuroprotective Agent Market?

The Home Care segment is expected to grow from 2.1 USD Billion to 4.3 USD Billion, indicating a robust demand. Read More

What is the anticipated growth for the Calcium Channel Blockers segment?

The Calcium Channel Blockers segment is projected to increase from 1.3 USD Billion to 2.2 USD Billion by 2035. Read More

What are the expected trends in the Neuroprotective Agent Market by 2035?

Trends suggest a continued focus on innovative therapies, particularly in Alzheimer's and Parkinson's Disease, driving market growth. Read More

What is the expected market size of the Global Neuroprotective Agent Market in 2024?

The Global Neuroprotective Agent Market is expected to be valued at 6.53 billion USD in 2024. Read More

How much is the Global Neuroprotective Agent Market projected to grow by 2035?

By 2035, the Global Neuroprotective Agent Market is projected to reach 12.3 billion USD. Read More

What is the compound annual growth rate (CAGR) for the Global Neuroprotective Agent Market from 2025 to 2035?

The expected CAGR for the Global Neuroprotective Agent Market from 2025 to 2035 is 5.92%. Read More

Which region holds the largest market share in the Global Neuroprotective Agent Market in 2024?

North America holds the largest market share, valued at 2.75 billion USD in 2024. Read More

What are the market values for Alzheimer's Disease in the Global Neuroprotective Agent Market for 2024 and 2035?

Alzheimer's Disease is valued at 2.1 billion USD in 2024 and is projected to grow to 4.0 billion USD by 2035. Read More

Who are the key players in the Global Neuroprotective Agent Market?

Major players include BristolMyers Squibb, Pfizer, Sanofi, Johnson and Johnson, and Eli Lilly among others. Read More

What is the market size for Parkinson's Disease in this market for 2024?

The market size for Parkinson's Disease in 2024 is valued at 1.2 billion USD. Read More

By how much is the market for Stroke expected to grow between 2024 and 2035?

The market for Stroke is expected to grow from 1.43 billion USD in 2024 to 2.75 billion USD by 2035. Read More

How is the Global Neuroprotective Agent Market segmented by region in 2035?

By 2035, the North America region is projected to reach 5.1 billion USD, while Europe is expected to reach 3.4 billion USD. Read More

What is the estimated market size for Multiple Sclerosis in 2035?

The market size for Multiple Sclerosis is projected to reach 1.7 billion USD in 2035. Read More

Neuroprotective Agent Market

ID: MRFR/HC/40499-HCR

100 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Neuroprotective Agent Market Research Report By Mechanism of Action (Antioxidants, Anti-inflammatory, Neurotransmitter Modulators, Calcium Channel Blockers), By Therapeutic Area (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Stroke), By Route of Administration (Oral, Injectable, Transdermal, Intranasal), By End User (Hospitals, Clinics, Home Care) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Neuroprotective Agent Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.6%

2024 Market Size$ 8.12 Billion

2025 Market Size$ 8.66 Billion

2035 Market Size$ 16.41 Billion

Key Players

Bristol Myers Squibb

Eli Lilly and Company

Pfizer Inc.

Novartis AG

Roche Holding AG

Teva Pharmaceutical Industries Ltd.

Trends

Rising Incidence of Neurological Disorders
Advancements in Biotechnology
Growing Interest in Preventive Healthcare

Opportunities

Rising Demand for Neuroprotective Agents
Rising Awareness of Preventive Healthcare
Increased Investment in Neuroscience Research

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Mechanism of Action (USD Billion) | |
  1. 4.1.1 Antioxidants | |
  2. 4.1.2 Anti-inflammatory | |
  3. 4.1.3 Neurotransmitter Modulators | |
  4. 4.1.4 Calcium Channel Blockers |
2. 4.2 Healthcare, BY Therapeutic Area (USD Billion) | |
  1. 4.2.1 Alzheimer's Disease | |
  2. 4.2.2 Parkinson's Disease | |
  3. 4.2.3 Multiple Sclerosis | |
  4. 4.2.4 Stroke |
3. 4.3 Healthcare, BY Route of Administration (USD Billion) | |
  1. 4.3.1 Oral | |
  2. 4.3.2 Injectable | |
  3. 4.3.3 Transdermal | |
  4. 4.3.4 Intranasal |
4. 4.4 Healthcare, BY End User (USD Billion) | |
  1. 4.4.1 Hospitals | |
  2. 4.4.2 Clinics | |
  3. 4.4.3 Home Care |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Bristol Myers Squibb (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Eli Lilly and Company (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Pfizer Inc. (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Novartis AG (CH) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Roche Holding AG (CH) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Teva Pharmaceutical Industries Ltd. (IL) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 AstraZeneca PLC (GB) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Merck & Co., Inc. (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 AbbVie Inc. (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY MECHANISM OF ACTION |
7. 6.4 US MARKET ANALYSIS BY THERAPEUTIC AREA |
8. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
9. 6.6 US MARKET ANALYSIS BY END USER |
10. 6.7 CANADA MARKET ANALYSIS BY MECHANISM OF ACTION |
11. 6.8 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA |
12. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
13. 6.10 CANADA MARKET ANALYSIS BY END USER |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY MECHANISM OF ACTION |
16. 6.13 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA |
17. 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
18. 6.15 GERMANY MARKET ANALYSIS BY END USER |
19. 6.16 UK MARKET ANALYSIS BY MECHANISM OF ACTION |
20. 6.17 UK MARKET ANALYSIS BY THERAPEUTIC AREA |
21. 6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
22. 6.19 UK MARKET ANALYSIS BY END USER |
23. 6.20 FRANCE MARKET ANALYSIS BY MECHANISM OF ACTION |
24. 6.21 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA |
25. 6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
26. 6.23 FRANCE MARKET ANALYSIS BY END USER |
27. 6.24 RUSSIA MARKET ANALYSIS BY MECHANISM OF ACTION |
28. 6.25 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
29. 6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
30. 6.27 RUSSIA MARKET ANALYSIS BY END USER |
31. 6.28 ITALY MARKET ANALYSIS BY MECHANISM OF ACTION |
32. 6.29 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA |
33. 6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
34. 6.31 ITALY MARKET ANALYSIS BY END USER |
35. 6.32 SPAIN MARKET ANALYSIS BY MECHANISM OF ACTION |
36. 6.33 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA |
37. 6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
38. 6.35 SPAIN MARKET ANALYSIS BY END USER |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY MECHANISM OF ACTION |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY MECHANISM OF ACTION |
45. 6.42 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA |
46. 6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
47. 6.44 CHINA MARKET ANALYSIS BY END USER |
48. 6.45 INDIA MARKET ANALYSIS BY MECHANISM OF ACTION |
49. 6.46 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA |
50. 6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
51. 6.48 INDIA MARKET ANALYSIS BY END USER |
52. 6.49 JAPAN MARKET ANALYSIS BY MECHANISM OF ACTION |
53. 6.50 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA |
54. 6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
55. 6.52 JAPAN MARKET ANALYSIS BY END USER |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY MECHANISM OF ACTION |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER |
60. 6.57 MALAYSIA MARKET ANALYSIS BY MECHANISM OF ACTION |
61. 6.58 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
62. 6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
63. 6.60 MALAYSIA MARKET ANALYSIS BY END USER |
64. 6.61 THAILAND MARKET ANALYSIS BY MECHANISM OF ACTION |
65. 6.62 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA |
66. 6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
67. 6.64 THAILAND MARKET ANALYSIS BY END USER |
68. 6.65 INDONESIA MARKET ANALYSIS BY MECHANISM OF ACTION |
69. 6.66 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA |
70. 6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
71. 6.68 INDONESIA MARKET ANALYSIS BY END USER |
72. 6.69 REST OF APAC MARKET ANALYSIS BY MECHANISM OF ACTION |
73. 6.70 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA |
74. 6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
75. 6.72 REST OF APAC MARKET ANALYSIS BY END USER |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY MECHANISM OF ACTION |
78. 6.75 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA |
79. 6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
80. 6.77 BRAZIL MARKET ANALYSIS BY END USER |
81. 6.78 MEXICO MARKET ANALYSIS BY MECHANISM OF ACTION |
82. 6.79 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA |
83. 6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
84. 6.81 MEXICO MARKET ANALYSIS BY END USER |
85. 6.82 ARGENTINA MARKET ANALYSIS BY MECHANISM OF ACTION |
86. 6.83 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA |
87. 6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
88. 6.85 ARGENTINA MARKET ANALYSIS BY END USER |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY MECHANISM OF ACTION |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY MECHANISM OF ACTION |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY MECHANISM OF ACTION |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER |
102. 6.99 REST OF MEA MARKET ANALYSIS BY MECHANISM OF ACTION |
103. 6.100 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA |
104. 6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
105. 6.102 REST OF MEA MARKET ANALYSIS BY END USER |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY MECHANISM OF ACTION, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY MECHANISM OF ACTION, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Neuroprotective Agent Market Segmentation

Neuroprotective Agent Market By Mechanism of Action (USD Billion, 2025-2035)

Antioxidants
Anti-inflammatory
Neurotransmitter Modulators
Calcium Channel Blockers

Neuroprotective Agent Market By Therapeutic Area (USD Billion, 2025-2035)

Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Stroke

Neuroprotective Agent Market By Route of Administration (USD Billion, 2025-2035)

Oral
Injectable
Transdermal
Intranasal

Neuroprotective Agent Market By End User (USD Billion, 2025-2035)

Hospitals
Clinics
Home Care

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”